Episode Details

Canada’s drug agency just flipped its stance on lecanemab, a groundbreaking Alzheimer’s treatment that targets brain plaques and slows early-stage decline. After reviewing new data, they now recommend public drug plans cover it — but only for patients with mild cognitive impairment, confirmed amyloid buildup, and regular MRI monitoring for risks like swelling or bleeding. Coverage ends if dementia progresses to moderate stage. Advocates are thrilled, calling it a lifeline that buys precious time for patients to maintain cognitive function and quality of life.

Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/f52e5a091e452ddf